JP2021511387A5 - - Google Patents

Info

Publication number
JP2021511387A5
JP2021511387A5 JP2020561600A JP2020561600A JP2021511387A5 JP 2021511387 A5 JP2021511387 A5 JP 2021511387A5 JP 2020561600 A JP2020561600 A JP 2020561600A JP 2020561600 A JP2020561600 A JP 2020561600A JP 2021511387 A5 JP2021511387 A5 JP 2021511387A5
Authority
JP
Japan
Prior art keywords
seq
monoclonal antibody
antigen
binding fragment
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020561600A
Other languages
English (en)
Japanese (ja)
Other versions
JP7458993B2 (ja
JP2021511387A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/015025 external-priority patent/WO2019147863A2/en
Publication of JP2021511387A publication Critical patent/JP2021511387A/ja
Publication of JP2021511387A5 publication Critical patent/JP2021511387A5/ja
Priority to JP2023221150A priority Critical patent/JP2024038169A/ja
Application granted granted Critical
Publication of JP7458993B2 publication Critical patent/JP7458993B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561600A 2018-01-25 2019-01-24 Mica/b抗体および使用方法 Active JP7458993B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023221150A JP2024038169A (ja) 2018-01-25 2023-12-27 Mica/b抗体および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862621892P 2018-01-25 2018-01-25
US62/621,892 2018-01-25
PCT/US2019/015025 WO2019147863A2 (en) 2018-01-25 2019-01-24 Mica/b antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023221150A Division JP2024038169A (ja) 2018-01-25 2023-12-27 Mica/b抗体および使用方法

Publications (3)

Publication Number Publication Date
JP2021511387A JP2021511387A (ja) 2021-05-06
JP2021511387A5 true JP2021511387A5 (cg-RX-API-DMAC7.html) 2022-02-01
JP7458993B2 JP7458993B2 (ja) 2024-04-01

Family

ID=67396240

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020561600A Active JP7458993B2 (ja) 2018-01-25 2019-01-24 Mica/b抗体および使用方法
JP2023221150A Pending JP2024038169A (ja) 2018-01-25 2023-12-27 Mica/b抗体および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023221150A Pending JP2024038169A (ja) 2018-01-25 2023-12-27 Mica/b抗体および使用方法

Country Status (10)

Country Link
US (2) US20210047417A1 (cg-RX-API-DMAC7.html)
EP (1) EP3743109A4 (cg-RX-API-DMAC7.html)
JP (2) JP7458993B2 (cg-RX-API-DMAC7.html)
KR (1) KR102731953B1 (cg-RX-API-DMAC7.html)
CN (1) CN112566659A (cg-RX-API-DMAC7.html)
AU (1) AU2019211411B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020015142A2 (cg-RX-API-DMAC7.html)
IL (1) IL276187B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020007880A (cg-RX-API-DMAC7.html)
WO (1) WO2019147863A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル-マイヤーズ スクイブ カンパニー Micaおよび/またはmicbに対する抗体ならびにそれらの使用
KR102832008B1 (ko) 2018-07-31 2025-07-10 컬리난 미카 코퍼레이션 Mica/b 유출을 차단하는 항-mica/b 항체 및 사용 방법
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
CN116547301A (zh) * 2020-08-10 2023-08-04 先天制药公司 使用抗体进行的细胞表面mica和micb检测
CN114369161B (zh) * 2021-12-28 2023-06-23 合肥天港免疫药物有限公司 Mica抗体及其应用
CN114369162B (zh) * 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
CN119998318A (zh) * 2022-04-08 2025-05-13 D2M生物治疗有限公司 抗mica/b抗体及其用途
CN116789823A (zh) * 2023-04-04 2023-09-22 浙江大学 用于检测mica脱落片段的结构域特异性抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1857116A1 (en) * 2006-05-19 2007-11-21 Novoplant GmbH Antigen binding polypeptides against spike glycoprotein (S2) of bovine coronavirus
BRPI0808551B1 (pt) * 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
US8753640B2 (en) * 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
DK2760471T3 (en) * 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
WO2014140904A2 (en) * 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
JP6450381B2 (ja) * 2013-07-05 2019-01-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション がんを処置するための可溶性mic中和モノクローナル抗体
KR102206029B1 (ko) * 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
HRP20220890T1 (hr) * 2015-02-06 2022-10-14 National University Of Singapore Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
EP3471761A2 (en) * 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof

Similar Documents

Publication Publication Date Title
JP2025111463A5 (cg-RX-API-DMAC7.html)
JP2023509448A5 (cg-RX-API-DMAC7.html)
JP2019536470A5 (cg-RX-API-DMAC7.html)
JP2018512379A5 (cg-RX-API-DMAC7.html)
JP2017536354A5 (cg-RX-API-DMAC7.html)
JP2022512132A5 (cg-RX-API-DMAC7.html)
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2019513018A5 (cg-RX-API-DMAC7.html)
IL280487B2 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
JP2017535257A5 (cg-RX-API-DMAC7.html)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2024520188A5 (cg-RX-API-DMAC7.html)
CN110799543A (zh) 肝细胞癌的免疫治疗
JP2023549537A5 (cg-RX-API-DMAC7.html)
JP2019527194A5 (cg-RX-API-DMAC7.html)
RU2016137110A (ru) Антитела к компоненту комплемента с5
JP2014529610A5 (cg-RX-API-DMAC7.html)
JP2024532489A5 (cg-RX-API-DMAC7.html)
JP2021525806A5 (cg-RX-API-DMAC7.html)
JP2020513759A5 (cg-RX-API-DMAC7.html)
JP2023506465A5 (cg-RX-API-DMAC7.html)
RU2019121106A (ru) Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
JP2021518748A5 (cg-RX-API-DMAC7.html)
JP2022500455A5 (cg-RX-API-DMAC7.html)
JP2022517216A5 (cg-RX-API-DMAC7.html)